| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Toyanji Joseph Punchaichira, Prachi Kukshal, Triptish Bhatia, Smita Neelkanth Deshpande, B K Thelm. Effect of rs1108580 of DBH and rs1006737 of CACNA1C on Cognition and Tardive Dyskinesia in a North Indian Schizophrenia Cohort. Molecular neurobiology. 2023-07-26. PMID:37493923. |
genetic perturbations in dopamine neurotransmission and calcium signaling pathways are implicated in the etiology of schizophrenia. |
2023-07-26 |
2023-08-14 |
human |
| Toyanji Joseph Punchaichira, Prachi Kukshal, Triptish Bhatia, Smita Neelkanth Deshpande, B K Thelm. Effect of rs1108580 of DBH and rs1006737 of CACNA1C on Cognition and Tardive Dyskinesia in a North Indian Schizophrenia Cohort. Molecular neurobiology. 2023-07-26. PMID:37493923. |
we aimed to test the association of a functional splice variant each in dopamine β-hydroxylase (dbh; rs1108580) and calcium voltage-gated channel subunit alpha1 c (cacna1c; rs1006737) genes in these pathways with schizophrenia (506 cases, 443 controls); abnormal involuntary movement scale (aims) scores in subjects assessed for tardive dyskinesia (76 td-positive, 95 td-negative) and penn computerized neurocognitive battery (penncnb) scores (334 cases, 234 controls). |
2023-07-26 |
2023-08-14 |
human |
| Takahiko Nagamin. PAIN THRESHOLD PARADOX IN SCHIZOPHRENIA: A NARRATIVE REVIEW BASED ON THE LASTEST NEUROSCIENCE. Psychiatria Danubina. vol 35. issue 2. 2023-07-22. PMID:37480304. |
as a result, a pain threshold paradox has been observed.many schizophrenia patients appear to have an excess of dopamine in the mesolimbic system, which stimulates both the descending pain inhibitory pathway and the salience network. |
2023-07-22 |
2023-08-14 |
Not clear |
| Jonathan M Meyer, Christoph U Correl. Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia. CNS drugs. 2023-07-20. PMID:37470979. |
an increased understanding of the pathophysiology of schizophrenia has guided discovery of novel treatments that do not directly target dopamine and that not only do not add, but may potentially minimize relevant cardiometabolic burden for these patients. |
2023-07-20 |
2023-08-14 |
Not clear |
| Pramod C Nair, Tarun Bastiampilla. Letter to the Editor: Letter to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia'. The Australian and New Zealand journal of psychiatry. 2023-07-19. PMID:37465954. |
letter to the editor: letter to the editor regarding 'a challenge to the dopamine orthodoxy in schizophrenia'. |
2023-07-19 |
2023-08-14 |
Not clear |
| William Lug. Letter to the Editor: Letter to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?' The Australian and New Zealand journal of psychiatry. 2023-07-19. PMID:37465967. |
letter to the editor: letter to the editor regarding 'a challenge to the dopamine orthodoxy in schizophrenia?' |
2023-07-19 |
2023-08-14 |
Not clear |
| Faiz M Kassim, J H Mark Lim, Sophie V Slawik, Katharina Gaus, Benjamin Peters, Joseph W Y Lee, Emily K Hepple, Jennifer Rodger, Matthew A Albrecht, Mathew T Martin-Iverso. The effects of caffeine and d-amphetamine on spatial span task in healthy participants. PloS one. vol 18. issue 7. 2023-07-13. PMID:37440493. |
previous reports also showed that increasing dopamine increases psychosis-like experiences (ple, or schizotypy) scores which are in turn negatively associated with wm performance in people with high schizotypy and people with schizophrenia. |
2023-07-13 |
2023-08-14 |
human |
| Pierre Baumann, Philipp Bauknecht, Maxim Kuzin, Georgios Schoretsaniti. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. International journal of psychiatry in clinical practice. 2023-07-10. PMID:37428441. |
switching antipsychotics to partial dopamine d2-agonists in individuals affected by schizophrenia: a narrative review. |
2023-07-10 |
2023-08-14 |
Not clear |
| Laramie Duncan, Karl Deisserot. Are novel treatments for brain disorders hiding in plain sight? Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2023-07-08. PMID:37422511. |
we focus on schizophrenia and the dopamine d2 receptor (drd2), hot flashes and the neurokinin b receptor (tacr3), cigarette smoking and receptors bound by nicotine (chrna5, chrna3, chrnb4), and alcohol use and enzymes that help to break down alcohol (adh1b, adh1c, adh7). |
2023-07-08 |
2023-08-14 |
human |
| Fumiaki Yamasaki, Nobuhisa Kanahara, Yusuke Nakata, Shinji Koyoshi, Yuta Yanagisawa, Takeru Saito, Takahiro Oiwa, Masanobu Kogure, Tsuyoshi Sasaki, Taisuke Yoshida, Hiroshi Kimura, Masaomi Iy. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England). 2023-07-03. PMID:37395368. |
can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? |
2023-07-03 |
2023-08-14 |
Not clear |
| Fumiaki Yamasaki, Nobuhisa Kanahara, Yusuke Nakata, Shinji Koyoshi, Yuta Yanagisawa, Takeru Saito, Takahiro Oiwa, Masanobu Kogure, Tsuyoshi Sasaki, Taisuke Yoshida, Hiroshi Kimura, Masaomi Iy. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England). 2023-07-03. PMID:37395368. |
several studies have reported that a switch to the dopamine partial agonist (dpa) aripiprazole (arp), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. |
2023-07-03 |
2023-08-14 |
Not clear |
| Yafei Kang, Youming Zhang, Kexin Huang, Zhenhong Wan. Association of dopamine-based genetic risk score with dynamic low-frequency fluctuations in first-episode drug-naïve schizophrenia. Brain imaging and behavior. 2023-06-29. PMID:37382826. |
alterations in dynamic intrinsic brain activity and signaling of neurotransmitters, such as dopamine, have been independently detected in schizophrenia patients. |
2023-06-29 |
2023-08-14 |
human |
| Yafei Kang, Youming Zhang, Kexin Huang, Zhenhong Wan. Association of dopamine-based genetic risk score with dynamic low-frequency fluctuations in first-episode drug-naïve schizophrenia. Brain imaging and behavior. 2023-06-29. PMID:37382826. |
we aimed to investigate the schizophrenia-specific dynamic amplitude of low frequency fluctuation (dalff) altered pattern, and its association with dopamine genetic risk score in first-episode drug-naïve schizophrenia (fes). |
2023-06-29 |
2023-08-14 |
human |
| Yafei Kang, Youming Zhang, Kexin Huang, Zhenhong Wan. Association of dopamine-based genetic risk score with dynamic low-frequency fluctuations in first-episode drug-naïve schizophrenia. Brain imaging and behavior. 2023-06-29. PMID:37382826. |
our findings indicate that cumulative dopamine genetic risk is associated with a known imaging phenotype for schizophrenia. |
2023-06-29 |
2023-08-14 |
human |
| Haiping Liu, Haixiang Ma, Xingyue Zeng, Chengyan Wu, Srijan Acharya, Sarabjeet Kour Sudan, Xiaohan Zhan. Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases. International journal of molecular sciences. vol 24. issue 12. 2023-06-28. PMID:37373182. |
understanding the signaling pathways downstream of d2r is critical for developing effective therapies with which to treat dopamine (da)-related disorders such as parkinson's disease and schizophrenia. |
2023-06-28 |
2023-08-14 |
Not clear |
| R Tabrisi, M D Harun-Rashid, J Montero, N Venizelos, M Msghin. Clozapine but not lithium reverses aberrant tyrosine uptake in patients with bipolar disorder. Psychopharmacology. 2023-06-15. PMID:37318540. |
availability of the dopamine and noradrenaline precursor tyrosine is critical for normal functioning, and deficit in tyrosine transport across cell membrane and the blood-brain barrier has been reported in bipolar disorder and schizophrenia. |
2023-06-15 |
2023-08-14 |
Not clear |
| Trevor R Norman, James S Olve. A challenge to the dopamine orthodoxy in schizophrenia? The Australian and New Zealand journal of psychiatry. 2023-06-02. PMID:37264935. |
a challenge to the dopamine orthodoxy in schizophrenia? |
2023-06-02 |
2023-08-14 |
Not clear |
| Jie Jia, Hualing Peng, Rui Tian, Hong Zhou, Hua Zheng, Bo Liu, Yisheng L. Gm527 deficiency in dentate gyrus improves memory through upregulating dopamine D1 receptor pathway. CNS neuroscience & therapeutics. 2023-05-30. PMID:37248637. |
dopamine d1 receptor (d1r) hypofunction is associated with negative and cognitive symptoms in schizophrenia; therefore, the mechanism of d1r function modulation needs further investigation. |
2023-05-30 |
2023-08-14 |
Not clear |
| Marco De Pieri, Marco Ferrari, Franca Marino, Rafael Traber, Emilio Bolla, Marco Cosentin. Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine. Frontiers in pharmacology. vol 14. 2023-05-25. PMID:37229261. |
cariprazine (car) is an antipsychotic drug for the treatment of schizophrenia (scz) and bipolar disorder (bd), and it acts as a partial agonist on the dopamine receptors (dr), d2, and d3. |
2023-05-25 |
2023-08-14 |
Not clear |
| Peiyu Xu, Sijie Huang, Brian E Krumm, Youwen Zhuang, Chunyou Mao, Yumu Zhang, Yue Wang, Xi-Ping Huang, Yong-Feng Liu, Xinheng He, Huadong Li, Wanchao Yin, Yi Jiang, Yan Zhang, Bryan L Roth, H Eric X. Structural genomics of the human dopamine receptor system. Cell research. 2023-05-23. PMID:37221270. |
the dopaminergic system, including five dopamine receptors (d1r to d5r), plays essential roles in the central nervous system (cns); and ligands that activate dopamine receptors have been used to treat many neuropsychiatric disorders, including parkinson's disease (pd) and schizophrenia. |
2023-05-23 |
2023-08-14 |
human |